is glp 1 patented Patent and Innovation Trends in GLP-1 and Weight Loss Drugs (2020–2025) Ozempic, Wegovy and Rybelsus: The
Description
Novo Nordisk was filed on December 15, 2023
In preclinical efficacy studies in diet-induced obese (DIO) mice and obese monkeys, treatment with AMG133 reduces body weight and improves metabolic parameters to a larger extent than a GLP-1 receptor agonist alone (50)
These medicines can improve blood sugar control, support weight loss, and in some cases reduce the risk of heart attack and stroke
Breast cancer survivors may also be taking other medicines, including hormonal therapies, which could potentially interact with metabolic treatments
